Bionyra Pharma
Next-generation biologics for immune-mediated inflammatory diseases
- Category
- Other
- Launched
- June 22, 2026
- Stage
- Series A
- Pricing
- paid
- Founder
- Dr. Frédéric Marrache
- Website
- bionyra.com
Bionyra Pharma is a clinical stage biopharmaceutical company developing next generation biologics for severe immune mediated inflammatory diseases. Its pipeline includes mono and multispecific antibodies with half life extension technology, targeting novel immune pathways for deeper and more durable disease control. The lead candidate, BYN 002, is a TL1A monoclonal antibody with half life extension (HLE) technology, currently in Phase 1 studies for inflammatory bowel disease (IBD) and other TL1A relevant indications. BYN 003 is a first in class TL1A IL 23p19 bispecific antibody with HLE, also in Phase 1. BYN 001 is an IL 25 monoclonal antibody with HLE in IND stage for atopic dermatitis and Type 2 inflammation. The company also has additional preclinical assets.
Discovered via